BGG issued patent on AstaZine natural astaxanthin for heart health
BGG World was issued a patent from the United States Patent and Trademark Office for the use of astaxanthin to support heart function during exercise (US Patent #10,827,775).
Photo © iStockphoto.com
BGG World (Irvine, CA) was issued a patent from the United States Patent and Trademark Office for the use of astaxanthin to support heart function during exercise (US Patent #10,827,775).
The patent is based on results from a clinical trial, sponsored by BGG, with amateur athletes preparing for a half marathon. Subjects supplementing BGG’s AstaZine natural astaxanthin experienced heart rates on average 10% lower during endurance training than the placebo group.
According to Shawn Talbott, lead researcher of the study, “Subjects were able to perform the same amount of ‘work’ but at lower cardiovascular ‘strain’ after supplementing with astaxanthin.”
Further, lead inventor of the patent and BGG’s global chief scientific officer, Yanmei Li, PhD, said in a press release, “BGG focuses on innovation by dedicating 5% of gross revenue to R&D. As a prime example of this policy, we are one of only a very small handful of astaxanthin producers sponsoring clinical research to validate our product and have published several astaxanthin clinical studies over the last few years. This patent is another example of how BGG supports our customers through our investment in research and constant innovation; we’ve successfully opened up a whole new area of health benefits for our astaxanthin customers to focus on.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
